Researchers at KAIST have developed a low-cost smartphone-based technology to detect hidden cameras by analyzing reflections from objects. The technology, called SweepLED, uses deep learning-based analysis to distinguish camera lenses from ordinary objects, achieving 94% detection accuracy. The technology has potential to be developed ...
A virtual e-health system (VIRTUES) has been found to be as safe and effective as standard care for monitoring cardiac implantable electronic devices, with significant cost savings and patient satisfaction. The system uses transmission reports from the patient's device to provide real-time monitoring and communication with the physician.
The AIR-STEMI trial found that functional coronary angiography significantly reduced major cardiovascular events and complications by 38% and 37%, respectively, compared to conventional angiography. The study showed that this approach can improve current care for high-risk patient populations by selecting and treating only clinically i...
A digital strategy identified untreated patients with heart failure and invited them for specialist evaluation, resulting in a more than doubling of guideline-recommended SGLT2 inhibitor therapy. The approach showed promise in increasing timely access to effective treatments for this major public health issue.
A randomized trial found that digital outreach improved short-term statin refill rates among patients with cardiovascular disease or high cardiovascular risk who had fallen behind on their prescriptions. Adaptive, sequential health system outreach strategies support improved cardiovascular prevention in population health programs.
A new study confirms the safety of rapid heart attack testing but finds no reduction in emergency department stay length. The 0/1-hour pathway was compared to the standard 0/3-hour pathway and was found to be noninferior in terms of safety.
Remote exercise-based cardiac rehabilitation shows promise as an additional option for patients, but does not replace centre-based rehabilitation. The study found that remotely delivered exercise improved physical capacity and was used by a substantial proportion of patients, despite not increasing overall participation.
The REACT study reveals that 57.1% of participants aged 18 to 70 had atherosclerotic plaques, despite no symptoms or previous diagnosis. Most people with coronary atherosclerosis also had the disease in other arteries, making portable ultrasound devices a promising screening tool.
A new study found that atorvastatin reduces major cardiovascular events by 30% in people aged 70 and older without known cardiovascular disease, diabetes, or dementia. However, it did not improve disability-free survival. The results inform treatment guidelines for older adults, who are underrepresented in previous trials.
The AMUNDSEN trial found that evolocumab significantly improved LDL-cholesterol goal achievement after a heart attack, but did not show early cardiovascular benefits. Patients who received evolocumab had a higher rate of LDL-C goal attainment compared to standard care.
A phase 2 clinical trial found that a monoclonal antibody targeting interleukin-6 achieved sustained reductions in inflammation biomarkers for six months in patients with chronic kidney disease. The therapy, known as pacibekitug, was well-tolerated and showed favorable effects on additional biomarkers associated with cardiovascular risk.
Starting evolocumab before or during percutaneous coronary intervention for acute myocardial infarction significantly reduces LDL cholesterol levels. However, this strategy does not improve short-term clinical outcomes, including death and cardiovascular hospitalization, during the first year. The study suggests that lowering LDL chole...
Pacibekitug, a long-acting monoclonal antibody targeting interleukin-6, produced sustained reductions in inflammatory markers in patients with chronic kidney disease. The treatment also showed dose-dependent effects on other inflammatory markers, such as fibrinogen and lipoprotein(a).
Atrial fibrillation patients with prior intracranial haemorrhage face uncertain stroke prevention strategies. Edoxaban trial findings indicate a need for individualised decision-making, highlighting increased bleeding risk in this population.
A study found that silent atherosclerosis is prevalent in 57.1% of adults, increasing with age and affecting men earlier than women. Conventional risk assessment often misses this disease, highlighting the need for early imaging detection and potential precision medicine approaches.
Atrial fibrillation patients who have had a heart attack may be at increased risk of bleeding if given potent antiplatelet therapy combined with direct oral anticoagulants. The EPIDAURUS trial found no significant benefits regarding cardiovascular events, suggesting these treatments may not be necessary for this patient population.
The PREMIUM trial suggests that dual antiplatelet therapy with a potent P2Y12 receptor inhibitor plus aspirin is recommended for up to 12 months after a STEMI. However, further studies are needed to determine the optimum antiplatelet regimen in patients after a STEMI.
The A-CLOSE trial found that extended dual antiplatelet therapy (DAPT) provides greater protection against cardiovascular events, but clopidogrel monotherapy reduces bleeding risk. Long-term antiplatelet strategies should be tailored to each patient's clinical characteristics.
The LIBREXIA ACS trial found that patients remain at risk of recurrent cardiovascular events after an acute coronary syndrome. No difference was observed in cardiovascular events or bleeding with milvexian compared to placebo, despite expected anticoagulant activity.
The SWITCH SWEDEHEART trial found prasugrel comparable to ticagrelor for major cardiovascular events, but with lower major bleeding risk. Prasugrel reduced major bleeding by 4.2% compared to ticagrelor.
A team from Tokyo Metropolitan University developed a system to test magnetohydrodynamic aerobraking for spacecraft reentry. They successfully generated strong magnetic fields using an electromagnet, exceeding previous results with permanent magnets.